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Background: The selective serotonin reuptake inhibitor fluoxetine (FLX) is widely used to treat depression and
anxiety disorders, but cellular mechanisms underlying the antidepressant effect of FLX remain largely unknown. The
generally accepted effect of chronic FLX treatment is increased adult neurogenesis in the hippocampal dentate
gyrus. It was recently demonstrated that FLX treatments can reverse the established neuronal maturation of granule
cells in the hippocampal dentate gyrus and of gamma-aminobutyric acidergic (GABAergic) interneurons in the
basolateral amygdala. However, it is not clear whether this dematuration effect of FLX occurs in other brain regions.
Thus, in this study, we used immunohistological analysis to assess the effect of FLX treatment on GABAergic
interneurons in the medial frontal cortex (mFC) and reticular thalamic nucleus (RTN).
Results: Immunofluorescence analysis for perineuronal nets (PNNs), which is a marker of neuronal maturation, and
for parvalbumin, calretinin, and somatostatin, which are markers for specific GABAergic interneuron type, showed
lower number of parvalbumin-positive (+) cells and PNN+/parvalbumin+ cells in the mFC of FLX-treated mice
compared to vehicle-treated mice. However, FLX treatment had no effect on the number of cells expressing
calretinin and somatostatin in the mFC. In the RTN, the number of PNN+ cells and parvalbumin+ cells was
unaltered by FLX treatments. Furthermore, the number of total GABA+ cells and apoptotic cells in the mFC was
similar between vehicle- and FLX-treated mice, suggesting that FLX treatment did not induce cell death in this
region. Rather, our findings suggest that the decreased number of parvalbumin+ cells in the mFC was due to a
decreased expression of parvalbumin proteins in the interneurons.
Conclusions: This study indicates that FLX decreases the levels of parvalbumin, a mature marker of fast-spiking
interneurons, and PNNs in parvalbumin+ interneurons in the mFC, suggesting that FLX treatment induces a
dematuration of this type of neurons. Induction of a juvenile-like state in fast-spiking inhibitory interneurons in
these regions might be involved in the therapeutic mechanism of this antidepressant drug and/or some of its
adverse effects.
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Fluoxetine (FLX), a selective serotonin reuptake inhibi-
tor (SSRI), is widely used to treat depressive disorder;
however, the cellular mechanisms underlying the
antidepressant effect of FLX remain unclear. Findings
from animal studies suggest that adult neurogenesis in
the brain is critically involved in this process [1]. It has
been reported that chronic FLX treatment for 2–4 weeks
results in increased neurogenesis and cell proliferation
in the adult dentate gyrus (DG) [2-4], a response that
has been linked to the behavioral effects of FLX [3]. Fur-
thermore, we recently demonstrated that chronic FLX
treatment leads to the generation of cortical gamma-
aminobutyric acidergic (GABAergic) interneurons from
neural progenitor cells in adult mice [5]. Conversely, we
have shown that chronic FLX treatment for more than
6 weeks decreases neurogenesis in the subventricular
zone of adult mice [6].
Besides its effect on adult neurogenesis, chronic FLX
treatments cause “dematuration,” a reversal of the
established state of maturation of adult dentate granule
cells [6-9], raising the possibility that a distinct form of
synaptic plasticity underlies the antidepressant effect
of FLX. Dentate granule cells in FLX-treated adult
mice exhibit similarity with immature granule cells in
non-treated mice in terms of expressions of maturation
cell markers (e.g., a decrease in calbindin expression
and an increase in calretinin expression) and electro-
physiological characteristics (e.g., reductions of basal
synaptic transmission and frequency facilitation of the
synapses between DG and CA3, and reinstatement of
high membrane excitability) [7]. A juvenile-like state of
granule cells has also been observed in the adult brains
of some genetically-engineered mice strains [10], such
as alpha calcium/calmodulin-dependent protein kinase
II (αCaMKII) heterozygous knockout (HKO) mice
[11-17], schnurri-2 (Shn-2) KO mice [18], and mutated
synaptosomal-associated protein 25 knock-in (SNAP-25
KI) mice [19]. Interestingly, FLX-induced dematuration of
neurons has also been observed in GABAergic interneu-
rons of the basolateral amygdala [20]; FLX converts
interneurons, in particular parvalbumin-positive (+) cells, a
subclass of interneurons, to a more immature state.
However, it remains unclear whether FLX has any effect on
cellular dematuration of interneurons in other brain
regions.
In this study, we used immunohistological analysis to
investigate the effect of FLX treatment on GABAergic
interneurons of the medial frontal cortex (mFC) and re-
ticular thalamic nucleus (RTN). Specifically, we assessed
whether FLX treatment demonstrated a dematuration
effect on GABAergic interneurons by examining the
expression of perineuronal net (PNN), a marker of
neuronal maturation, as well as the expression ofparvalbumin, calretinin, and somatostatin, which are
markers for specific GABAergic interneurons.
Results
Chronic FLX treatment decreased the number of
parvalbumin+ cells in the frontal cortex
PNNs are reticular structures composed of extracellular
matrix molecules, such as chondroitin sulfate proteogly-
cans, hyaluronan, and tenascin-R, and are expressed in
the central nervous system [21]. The temporal pattern of
PNN formation reportedly corresponds to the ending of
the critical periods in which synaptogenesis, synaptic re-
finement, and myelination occur [21], thus suggesting
that their formation coincides with neuronal maturation.
For this reason, PNNs are considered a marker of neur-
onal maturation [20,22,23].
Using PNN and parvalbumin stained sections, we first
examined whether chronic FLX treatment altered the
staining pattern of parvalbumin+ cells in the mFC of
adult mice. FLX solution was intraperitoneally injected
into mice at 15 mg · kg-1 · day-1 for 3 weeks. We chose
the mFC (Additional file 1: Figure S1), because it exten-
sively overlaps with regions referred to as the anterior
cingulate cortex [24] and because it plays an important
role in rodent emotional memory and behavior associ-
ated with limbic regions, such as the amygdala and
hippocampus [25-27]. The number of parvalbumin+
cells in the mFC was significantly decreased in FLX-
treated mice compared to vehicle-treated mice (Figure 1;
p = 0.0049). There was no significant difference in the
number of total PNN+ cells between FLX- and vehicle-
treated mice, although the number of PNN+ cells tended to
decrease by chronic FLX treatment (p = 0.072). Chronic
FLX treatment significantly decreased the number of
parvalbumin+/PNN+ cells (p = 0.00024). Using these data,
we calculated the percentage of parvalbumin+/PNN+ cells
from the total number of parvalbumin+ cells and found
that FLX treatment decreased the percentage of
parvalbumin+/PNN+ cells to approximately 80% of the
vehicle-treated value (p = 0.00033).
We also investigated whether FLX treatment affected
the number of parvalbumin+ cells in the RTN. In the
RTN, in which almost all neurons are GABAergic,
FLX treatment had no effect on the numbers of
parvalbumin+ (p = 0.54) and PNN+ cells (p = 0.36)
(Figure 2C and D). However, we found a significantly
lower number of parvalbumin+ cells in the hippocam-
pal CA3 region of FLX-treated mice compared to
vehicle-treated mice (Figure 2A and B; p = 0.00063).
The number of PNN+ cells was also significantly de-
creased in the hippocampal CA3 region (Figure 2A and
B; p = 0.040) but not in the RTN. FLX treatment also
reduced the number of parvalbumin+ cells in the
basolateral amygdala (Additional file 1: Figure S2;
AB
Figure 1 Decrease in the number of parvalbumin+ cells in the mFC. (A) Representative coronal images of parvalbumin+ (magenta)/PNN+
(green) cells in the mFC of mice treated with vehicle (upper row) or FLX (lower row). Mice received FLX for 3 weeks at 15 mg/kg/day.
(B) Quantification of the number of parvalbumin+, PNN+, parvalbumin+/PNN+ cells, and the proportion of parvalbumin+/PNN+ cells in the
total number of parvalbumin+ cells (n = 4 mice each; 11-week-old). FLX, fluoxetine; PNN, perineuronal net; PV, parvalbumin.
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region and basolateral amygdala corroborate previous
findings [20].
Chronic FLX treatment did not alter the numbers of
calretinin+ and somatostatin+ cells
Three main subgroups of GABAergic interneurons are
found in the FC of adult rodents: parvalbumin+ cells,
calretinin+ cells, and somatostatin+ cells [28]. Thus, we
next examined whether chronic FLX treatment de-
creased the expression of calretinin and somatostatin in
the mFC, RTN, hippocampus, and basolateral amygdala.
Chronic FLX treatment had no effect on the number of
calretinin+ and somatostatin+ cells in these brain regions
(Additional file 1: Figure S3 and Table S1). In addition,
the calretinin+ and somatostatin+ cells in the mFC,
RTN, hippocampus, and basolateral amygdala were not
surrounded by PNNs (Additional file 1: Figure S3 andTable S1), which is consistent with previous findings
[29,30]. Although calbindin was abundantly expressed in
the RTN, FLX treatment did not alter its expression
(Additional file 1: Figure S3 and Table S1). This result
suggests that FLX treatment mainly affected parvalbumin+
interneurons, and not calretinin and somatostatin, in the
mFC, hippocampus, and basolateral amygdala. It also high-
lights that compared to calretinin+ and somatostatin+ cells,
parvalbumin+ cells are more likely to be surrounded by
PNNs.
Chronic FLX treatment did not alter the numbers of GABA+
cells and apoptotic cells
Although we had observed a significant decrease in the
number of parvalbumin+ cells in the mFC and hippo-
campus of FLX-treated mice, it remained unclear
whether this decrease was reflective of parvalbumin+
interneuron cell death or a decrease in the expression of
Figure 2 (See legend on next page.)
Ohira et al. Molecular Brain 2013, 6:43 Page 4 of 11
http://www.molecularbrain.com/content/6/1/43
(See figure on previous page.)
Figure 2 Expression of parvalbumin and PNN in the hippocampal CA3 and RTN. (A, C) Double-staining for parvalbumin (magenta) and
PNN (green) in coronal sections of the hippocampal CA3 region (A) and RTN (C). Mice received FLX for 3 weeks at 15 mg/kg/day. (B, D) The
number of parvalbumin+, PNN+, parvalbumin+/PNN+ cells, and the proportion of parvalbumin+/PNN+ cells in the total number of parvalbumin+
cells were quantified in the hippocampal CA3 region (B) and RTN (D) (n = 4 mice each; 11-week-old). Note that a decreased number of
parvalbumin+ cells were found in the hippocampal CA3, but not in the RTN. CA, cornu ammonis; FLX, fluoxetine; PNN, perineuronal net; PV,
parvalbumin; RTN, reticular thalamic nucleus.
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performed immunofluorescence staining for GABA to
examine the effect of FLX treatment on the total num-
bers of GABAergic interneurons in these regions. We
found no difference in the number of GABA+ cells in
the mFC (Figure 3A and B; p = 0.82) and hippocampus
(Figure 3C and D; p = 0.81) of FLX-treated mice com-
pared to vehicle-treated mice. Furthermore, the fluores-
cence intensity of GABA in the mFC and hippocampus
of FLX-treated mice was similar to that in these regions
of vehicle-treated mice (Figure 3B and D; mFC, p = 0.57;
Hippocampal CA3, p = 0.53). We subsequently examined
whether the number of apoptotic cells changed afterA B
C D
Figure 3 FLX treatment did not change the number of GABA+ cells in
of GABA+ cells in the mFC (A) and hippocampus (C) of vehicle-treated (up
15 mg/kg/day. (B, D) The number of GABA+ cells (left graphs) and the fluo
(B) and hippocampal CA3 region (D) of vehicle-treated and FLX-treated m
mFC, medial frontal cortex.FLX treatments. Terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) analysis re-
vealed that FLX treatments did not induce apoptotic cell
death in the mFC and hippocampus (Additional file 1:
Figures S4). In addition, we labeled the interneurons
with 5-bromodeoxyuridine (BrdU), a marker of DNA
synthesis, by intraperitoneal injection of BrdU into
timed-pregnant mice every 24 h from day 14 to day 20
of gestation. Thus, the interneurons generated during
the embryonic period contained BrdU. FLX treatment
was commenced 8 weeks after birth and continued for
3 weeks. FLX treatment did not alter the number of
BrdU+ cells in the mFC or hippocampus; however, itthe mFC and hippocampus. (A, C) Representative coronal images
per) and FLX-treated mice (lower). Mice received FLX for 3 weeks at
rescence intensity of GABA (right graphs) were quantified in the mFC
ice (n = 4 mice each; 11-week-old). CA, cornu ammonis; FLX, fluoxetine;
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+ cells (Additional file 1: Figures S5 and S6). This result
suggests that, in the cells generated during embryogen-
esis, parvalbumin protein levels in the mFC and
hippocampus were reduced after FLX treatment. Taken
together, these findings suggest that the decreased num-
ber of parvalbumin+ cells in the mFC and hippocampus
may reflect a decreased expression of parvalbumin
proteins in each interneuron.
Discussion
In this study, we examined the effect of chronic FLX
treatment on PNN expression as well as the expression
of parvalbumin+, calretinin+, and somatostatin+ cells in
the mFC, hippocampus, basolateral amygdala, and RTN.
Immunofluorescence analysis revealed that FLX treat-
ment decreases the number of parvalbumin+ cells,
but not that of calretinin+ or somatostatin+ cells, in
the mFC, hippocampus, and basolateral amygdala.
Our findings suggest that the decreased number of
parvalbumin+ cells reflects a decrease in parvalbumin
protein expression in each interneuron, and not apop-
totic cell death of parvalbumin+ cells or a decrease in
the total number of GABA+ cells. Furthermore, the per-
centage of parvalbumin+/PNN+ cells was also decreased
in the mFC. These findings suggest that FLX treatment
may have a dematuration effect on fast-spiking inhibi-
tory interneurons in the mFC and hippocampus, which
are immunoreactive for parvalbumin during the mature
status [31]. This pseudo-immature state of parvalbumin
+ cells may account for the antidepressant effect of FLX,
in addition to, or as an alternative to, dematuration in
the DG and amygdaloid neurons and increased neuro-
genesis in the DG and cortex.
Decreased percentage of PNN+ cells out of parvalbumin+
cells in the mFC
In the present study, we found a decrease in the
number of PNN+ cells in the hippocampal CA3
region and a decrease in the proportion of PNN
+/parvalbumin+ cells in the total number of
parvalbumin+ cells in the mFC, basolateral amygdala,
and hippocampal CA3 region. It has previously been
demonstrated that chronic FLX treatment decreases
the percentage of PNN+/parvalbumin+ cells (from
the total number of parvalbumin+ cells) in the
basolateral amygdala and hippocampal CA1 [20];
however, to our knowledge, such a finding has not
been observed in the FC until now. In contrast to our
study, a previous study reported no disruption to PNNs in
the FC [20]. This difference may be attributable to the dif-
ferences in FLX administration, such as the dose of FLX
(10 mg · kg-1 ∙ day-1 in the previous study vs. 15 mg ∙ kg-1 ∙
day-1 in this study) and administration method (drinkingwater in the previous study vs. intraperitoneal injection in
this study). This discrepancy in findings for PNN expres-
sion in the mFC should be examined in future studies to
determine whether it is a dose-dependent effect of FLX.
The formation of PNNs coincides with neuronal mat-
uration in the central nervous system [20,22,23]. Thus,
similar to other studies, we used PNN as a marker of
neuronal maturation. We found a significant decrease
in PNN+ cells in the hippocampal CA3 region follow-
ing FLX treatment; however, FLX treatment had
less effect on the total number of PNN+ cells in
the mFC. This is probably because the reduction of
PNN happens specifically in the parvalbumin+ cells
in the mFC. Also, it may be due to the long life
of PNN components. It has previously been demon-
strated that the immunoreactivity of PNN compo-
nents, tenascin and chondroitin sulphate proteogly-
cans, persists in vivo for at least up to 4 weeks and
14 months, respectively [32]. In this study, we used
Wisteria floribunda lectin (WFA) to detect PNNs.
WFA binds carbohydrate structures terminating
in N-acetylgalactosamine linked to galactose, which
are contained in chondroitin sulphate proteoglycans
of PNNs [32]. Thus, this suggests that dematur-
ated interneurons are still surrounded by PNNs or
chondroitin sulphate proteoglycans after the disap-
pearance of parvalbumin proteins in each interneuron.
Consequently, fast-spiking cells, in which parvalbumin
proteins are diminished by FLX treatment, can be
detected by WFA.
No significant differences were observed in the
numbers of parvalbumin+ or PNN+ cells in the RTN
between vehicle- and FLX-treated mice. Currently, it
is not clear why these numbers did not change after
FLX treatment. However, possibly, this could be at-
tributable to the origins of the GABAergic interneu-
rons present in the regions. Almost all the cortical,
hippocampal, and amygdaloid GABAergic interneu-
rons are derived from the ventricular zone of the
medial and caudal ganglionic eminences [33,34], while
thalamic GABAergic interneurons originate from the
ventricular zone of the third ventricles [35]. These re-
sults suggest the possibility that FLX treatment might
specifically reduce parvalbumin protein levels in inter-
neurons derived from the ganglionic eminences. It
will be interesting to examine this, as well as other
possibilities, in future research.
Decrease in the number of parvalbumin+ cells in the mFC
and hippocampus
In this study, we demonstrated that chronic FLX treat-
ment did not induce apoptotic cell death of parvalbumin+
interneurons in the mFC and hippocampus. We also
showed that the number of GABA+ cells in the mFC and
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These findings suggest that the decreased number of
parvalbumin+ cells reflects a decrease in expression
of parvalbumin proteins in each cell.
Three main subgroups of GABAergic interneurons are
found in the FC of adult rodents: parvalbumin+,
calretinin+, and somatostatin+ cells [28]. On the other
hand, based on the firing patterns for depolarization,
cortical GABAergic interneurons are divided into
three subgroups: fast-spiking, late-spiking, and regular-
spiking/burst-spiking non-pyramidal cells [36]. It is
widely accepted that almost all fast-spiking interneurons
express parvalbumin, whereas interneurons with the
other types of spiking patterns have calretinin and som-
atostatin [36]. In rodents, almost all fast-spiking inhibi-
tory GABAergic interneurons in both cortex [37] and
hippocampus [38] are generated during the embryonic
period, while the first parvalbumin proteins appear at
postnatal day 10 in the mouse cortex [39] and at postna-
tal day 7 in the hippocampus [40]. Moreover, using tran-
scriptional and electrophysiological analyses of a GFP
knock-in mice, in which almost all fast spiking inhibi-
tory interneurons express GFP, fast-spiking inhibitory
interneurons have been reported to mature between
P10 and P25 [31,41]. Thus, immature fast-spiking in-
hibitory interneurons in the cortex do not express
parvalbumin mRNA. The present result suggests that
FLX treatment may convert mature parvalbumin+ inter-
neurons to a pseudo-immature state, i.e., FLX treatment
may cause “dematuration” of parvalbumin+ interneu-
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Figure 4 Dematuration of cortical fast-spiking inhibitory
interneurons by FLX treatments. Based on parvalbumin
expression, the state of the dematurated fast-spiking inhibitory
interneurons in the mFC of FLX-treated mice were similar to that of
fast-spiking inhibitory interneurons of non-treated mice between
postnatal days 0 and 10 (indicated in yellow). E, embryonic day; P,
postnatal day.Implication of FLX-induced neuronal dematuration in the
mFC, hippocampus, and amygdala
In adult mice, FLX treatment converts differentiated DG
neurons to a more immature state [6-9]. Similar changes
in DG neurons have been demonstrated in αCaMKII
HKO [11], Shn-2 KO [18], and SNAP-25 KI mice [19];
this phenomenon has been termed the “immature DG”
[10]. In this study, we demonstrate for the first time
that FLX treatment might also induce dematuration of
parvalbumin+ interneurons in the mFC and hippocam-
pal CA3 region, while our finding in the amygdala is
consistent with that of a previous study [20]. Consist-
ently, the present study demonstrates that chronic FLX
treatment increases the expression of polysialic acid-
neural cell adhesion molecule (PSA-NCAM), which is a
marker for immature neurons and a regulator of
neural plasticity [42,43], in the mFC, hippocampus, and
amygdala; this is in agreement with previous findings
[44,45] (Additional file 1: Figure S7). This suggests that
dematuration of parvalbumin+ interneurons is induced
by FLX treatment in the mFC, hippocampus, and amyg-
dala, where neural plasticity might be enhanced by FLX
treatment. In line with this, FLX treatment has been
reported to reinstate neural plasticity and promote the
electrophysiological and behavioral recovery of functions
in the visual cortex of adult amblyopic rats [46]. In
contrast, accelerated maturation of parvalbumin+ cells
via overexpression of the neurotrophin brain-derived
neurotrophic factor leads to a reduced capacity for cor-
tical neural plasticity [47,48]. Thus, dematuration of
parvalbumin+ interneurons in the mFC, hippocampus,
and amygdala might reinstate synaptic plasticity that is
reduced with age and development, thereby potentially
causing the antidepressant effect of FLX. Further studies
are required to address the causal relationship between
dematuration of parvalbumin+ cells and enhanced neural
plasticity.
Recent findings have led to the hypothesis that prob-
lems in information processing within neural networks,
rather than altered chemical balance, may account for
the mechanism underlying depression [49,50]. Thus,
antidepressant drugs may induce changes in neuronal
morphology and connectivity, gradually improving neur-
onal information processing and recovering mood. In-
deed, volume changes in the hippocampus, mPFC, or
amygdala are found both in patients with depression and
in animal models of depression [51,52]. Previous studies,
as well as the present one, have identified some of the
effects of FLX on the brain, which include increased
adult neurogenesis in the DG [2] and cortex [5], de-
creased adult neurogenesis in the SVZ [6], dematuration
of neurons in the DG [7], amygdala [20], and mFC. Most
events occur in the FC and limbic system. Interestingly, it
has become increasingly clear that network dysfunction in
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amygdala, is involved in the pathophysiology of depressive
disorder [24,53,54]. Therefore, neuronal dematuration and
adult neurogenesis in these regions may play important
roles in the mechanism of action of antidepressant drugs
like FLX. In addition, some of the adverse effects of FLX
[55], such as aggression, violence, and psychosis, might be
mediated by the dematuration of fast-spiking inhibitory in-
terneurons in the mFC. Aggression and violence are associ-
ated with deficits in the prefrontal cortex of humans
[56,57], where activation of GABAergic interneurons de-
creases [57]. Dematuration of fast-spiking inhibitory inter-
neurons might decrease inhibitory transmission of the
interneurons, which in turn could evoke aggression and
violence. It should be noted that, in post-mortem brains of
patients with schizophrenia, the number of parvalbumin+
interneurons [41,58] and PNN+ cells [59] is decreased in
the prefrontal cortex. This dematuration of parvalbumin+
fast-spiking interneurons by FLX treatment may be related
to the antidepressant-induced psychosis and agression ob-
served in clinical settings [55,60]. Future studies will need
to address the behavioral significance of the FLX-induced
dematuration effect on fast-spiking inhibitory interneurons
in the mFC.
Conclusions
The present study demonstrates that chronic FLX treat-
ment reduces parvalbumin proteins and PNNs in
GABAergic interneurons in the mFC, suggesting that
FLX induces juvenile-like state of fast-spiking inhibitory in-
terneurons in mFC. This effect of FLX on parvalbumin+
cells in the mFC might account for the therapeutic
mechanism of this antidepressant drug and/or some of
its adverse effects.
Methods
Animals and antidepressant treatment
Adult male C57BL/6 J mice (Charles River Laboratories
Japan, Yokohama, Japan), that were 2 months old at the
start of our experiments, were used. All animal experi-
ments were approved by the Institutional Animal Care
and Use Committee of Fujita Health University, based
on the Law for the Humane Treatment and Manage-
ment of Animals (2005) and the Standards Relating to
the Care and Management of Laboratory Animals and
Relief of Pain (2006). Every effort was made to minimize
the number of animals used.
Treatment with FLX (LKT Laboratories, St. Paul, MN)
was performed as previously described [5]. Briefly, FLX
solution was intraperitoneally injected into mice be-
tween 10:00–11:00 a.m. every day for 3 weeks. The ap-
propriate FLX concentration (15 mg ∙ kg-1 ∙ day-1) was
determined for each body weight before injection. Mice
were fixed at 6 h after the last injection of FLX. ChronicFLX treatment at this concentration remarkably decreased
the expression of calbindin in the DG (Additional file 1:
Figure S8; p = 0.00046), as previously reported [6,7].BrdU labeling
BrdU injection was performed as previously described
[14]. Briefly, the BrdU (Sigma-Aldrich, St. Louis, MO)
stock solution was prepared in distilled water with
0.007 N NaOH at 20 mg/ml and stored at −20°C until
use. In order to label GABAergic interneurons of the
embryonic cerebral cortex with BrdU, timed-pregnant
mice were intraperitoneally injected with BrdU solution
(100 mg/kg body weight) dissolved in phosphate buff-
ered saline (PBS) every 24 h from day 14 to day 20 of
gestation. After birth, the mice were bred for 2 months
before subsequently receiving FLX injections for 3 weeks
at a concentration at 15 mg ∙ kg-1 ∙ day-1. The mice were
deeply anesthetized and transcardially perfused with
4% paraformaldehyde in 0.1 M phosphate buffer (PB),
pH 7.4. For staining BrdU staining, sections were
pretreated with HCl as previously described [14].Immunohistological analysis
Fixation and immunofluorescence staining were performed
as previously described [5]. Briefly, mice were deeply anes-
thetized with chloral hydrate (245 mg/kg, intraperitoneally)
and transcardially perfused with 4% paraformaldehyde in
0.1 M PB. The brains were dissected, immersed overnight
in the same fixative, and transferred to 30% sucrose in PBS
for at least 3 days for cryoprotection. All brain samples
were mounted in Tissue-Tek (Miles, Elkhart, IN), frozen,
and cut coronally into 50-μm-thick coronal sections, using
a microtome (CM1850, Leica Microsystems, Wetzlar,
Germany). Sections were stored in PBS containing sodium
azide (0.05%, w/v) at 4°C until use. After washing in PBS
for 1 h, they were preincubated with PBS-DB (4% normal
donkey serum [Vector Laboratories, Burlingame, CA] and
1% BSA in PBS) for 2 h at room temperature. The sections
were incubated at 4°C for 48 h or at room temperature
overnight with the indicated primary antibodies. After
washing in PBS for 1 h, the sections were incubated at
room temperature for 1 h with secondary antibodies. For
PNN staining, the sections were incubated with biotinylated
WFA (1:200; Sigma-Aldrich) at 4°C for 48 h or at room
temperature overnight. After washing in PBS for 1 h,
the sections were incubated with Alexa Fluor 488
conjugated to streptavidin (10 μg/ml; Life technologies,
Carlsbad, CA) for 1 h at room temperature. After
washing in PBS containing Hoechst 33258 for nuclear
counterstaining for 1 h, the sections were mounted on
glass slides coated with 3-aminopropyltriethoxysilane
and embedded with Permafluor (Thermo Scientific,
Pittsburgh, PA). Confocal laser-scanning microscopy
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to obtain images of the stained sections.
Antibodies
The following primary antibodies were used: mouse mono-
clonal antibodies for calbindin (1:2000, Sigma-Aldrich),
parvalbumin (1:2000, Sigma-Aldrich), PSA-NCAM (clone
2-2B mouse IgM; 1:200, Millipore, Billerica, MA); rat
monoclonal antibody for BrdU (1:100, Abcam, Cambridge,
MA); and rabbit polyclonal antibodies for calretinin (1:500,
Life technologies), GABA (1:1000, Sigma-Aldrich), and
somatostatin (1:1000, Bachem, Bubendorf, Switzerland).
The following secondary antibodies were used: goat anti-
mouse IgG Alexa Fluor 488 (1:200, Life Technologies), goat
anti-mouse IgG Alexa Fluor 594 (1:200, Life Technologies),
goat anti-mouse IgM Cy3 (1:200, Millipore), goat anti-
rabbit IgG Alexa Fluor 594 (1:200, Life Technologies),
and goat anti-rat IgG Alexa Fluor 594 (1:200, Life
Technologies).
TUNEL staining
TUNEL staining was performed according to the manu-
facturer’s instructions (in situ cell death detection kit,
Roche, Mannheim, Germany).
Ischemia treatment
Global ischemia was induced as previously described
[61]. Briefly, after anesthesia, both common carotid ar-
teries were transiently occluded with clamps for 10 min.
Control animals were treated identically, except for the
occlusion of common carotid arteries. The mice were
allowed to survive for 2 days after ischemia and were
then killed by perfusion.
Quantification of labeled cells
The mFC region was determined according to the
mouse brain atlas [62]. Quantification analysis was
performed as previously reported [5]. Briefly, analysis
was performed using a confocal microscope equipped
with a 40 × objective lens (Plan-NEOFLUAR, NA = 0.75,
Carl Zeiss) and a pinhole setting that corresponded to a
focal plane thickness of less than 1 μm. To exclude
false-positives due to the overlay of signals from differ-
ent cells, randomly selected areas were analyzed by mov-
ing through the entire z-axis of each area. Cells were
counted under the live mode of confocal scanning. For
quantifying the fluorescence intensity of immunostained
images, we used the ImageJ software. The region of
interest of the acquired images was traced, and optical
densities were obtained from at least three sections per
mouse. Background intensity was subtracted using
nonstained portions of each section. Slides were coded
and quantified by a blinded independent observer. Datawere analyzed by one-way ANOVA. The error bars in
the figures represent SEM.
Additional file
Additional file 1: Figures pertaining to chronic FLX treatment.
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